The Latest Breaking News from Abbott Laboratories

While high inflation and GDP decline for two consecutive quarters are raising recession fears, better-than-expected corporate profits and the possibility of a less aggressive rate hike have been restoring investor confidence. Regardless of the uncertainties surrounding the economy and the market, investing in Abbott Laboratories (ABT), Coca-Cola Consolidated (COKE), DLH…

Healthcare company Abbott Labs (ABT) has demonstrated solid growth over the past years. Moreover, the company announced its plans to restart its baby formula business in Michigan. And considering its fundamental strength, we think the stock might be an ideal investment for long-term growth. Read on….

Leading healthcare company Abbott Laboratories (ABT) reported strong second-quarter results. And given the company is well-positioned to capitalize on its diverse business and recent FDA approvals, is it wise to buy the stock now? Let’s find out.

Abbott Laboratories reported strong earnings Wednesday, despite spending recent months responding to criticism over problems that led to the shutdown of one of its infant formula-producing plants.

Pre-open movers

Leading healthcare company Abbott Laboratories (ABT) reported robust first-quarter results. And the company is well-positioned to benefit from its diversified business. Moreover, as ABT is resuming infant formula production at its Michigan facility, is the stock a good buy at the current price level? Read more to find out….

Diversified healthcare company Abbott (ABT) has demonstrated significant innovations across its segments, and given its dominant market position, the company’s prospects look bright. The stock could be a solid choice as it is well-positioned to survive short-term market fluctuations. Let’s discuss this in detail….

Abbott Laboratories (NYSE:ABT) has observed the following analyst ratings within the last quarter:

Abbott Laboratories (NYSE:ABT) has outperformed the market over the past 5 years by 7.3% on an annualized basis producing an average annual return of 17.14%. Currently, Abbott Laboratories has a market capitalization of $187.96 billion.

Medical device company Abbott Laboratories (ABT) reported impressive first-quarter results and affirmed its strong performance guidance for fiscal 2022. Furthermore, the company is well-positioned to benefit from its diversified business. However, amid the heightened market volatility, the stock is trading 25.5% below its 52-week high. So, the current dip in…

Problems for Abbott Laboratories' (NYSE: ABT) Sturgis plant in Michigan for baby formula powder refuse to subside. The FDA was recently notified of another infant's death who was given formula made at Abbott's Sturgis facility.